New simple and quick method to analyze serum variant transthyretins: direct MALDI method for the screening of hereditary transthyretin amyloidosis.
Hereditary transthyretin amyloidosis
Mass spectrometry
Variant transthyretin
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
27 05 2019
27 05 2019
Historique:
received:
27
12
2018
accepted:
19
05
2019
entrez:
29
5
2019
pubmed:
28
5
2019
medline:
26
11
2019
Statut:
epublish
Résumé
Hereditary transthyretin amyloidosis (ATTRv amyloidosis) is caused by a variant transthyretin (TTR), which is a serum protein secreted by the liver. Mass spectrometry (MS) is a useful tool that can detect variant TTRs in serum samples from patients with ATTRv amyloidosis. We previously reported several mass spectrometric methods to detect variant TTRs in serum samples. Those methods require cumbersome immunoprecipitation with anti-TTR antibodies and significant time to analyze the variant TTRs. In our study here, we developed a new simple and quick method to detect variant TTRs in serum samples by means of matrix-assisted laser desorption-ionization time-of-flight (MALDI-TOF) MS without immunoprecipitation (direct MALDI). By using direct MALDI, we analyzed 288 serum samples obtained from patients who were clinically suspected having amyloidosis to investigate the usefulness of this direct MALDI method to detect variant TTRs in serum samples. The method completed the process within 30 min. We successfully identified variant TTRs in serum samples from patients, except for a few patients with TTR Glu61Lys and Glu89Gln mutations because of the small mass shift of those variant TTRs from wild-type TTR. We also found that the mass shifts of variant TTRs measured by direct MALDI corresponded to theoretical mass changes. Our results suggest that the direct MALDI method is useful for the screening of ATTRv amyloidosis.
Sections du résumé
BACKGROUND
Hereditary transthyretin amyloidosis (ATTRv amyloidosis) is caused by a variant transthyretin (TTR), which is a serum protein secreted by the liver. Mass spectrometry (MS) is a useful tool that can detect variant TTRs in serum samples from patients with ATTRv amyloidosis. We previously reported several mass spectrometric methods to detect variant TTRs in serum samples. Those methods require cumbersome immunoprecipitation with anti-TTR antibodies and significant time to analyze the variant TTRs. In our study here, we developed a new simple and quick method to detect variant TTRs in serum samples by means of matrix-assisted laser desorption-ionization time-of-flight (MALDI-TOF) MS without immunoprecipitation (direct MALDI).
METHODS
By using direct MALDI, we analyzed 288 serum samples obtained from patients who were clinically suspected having amyloidosis to investigate the usefulness of this direct MALDI method to detect variant TTRs in serum samples.
RESULTS
The method completed the process within 30 min. We successfully identified variant TTRs in serum samples from patients, except for a few patients with TTR Glu61Lys and Glu89Gln mutations because of the small mass shift of those variant TTRs from wild-type TTR. We also found that the mass shifts of variant TTRs measured by direct MALDI corresponded to theoretical mass changes.
CONCLUSION
Our results suggest that the direct MALDI method is useful for the screening of ATTRv amyloidosis.
Identifiants
pubmed: 31133063
doi: 10.1186/s13023-019-1100-y
pii: 10.1186/s13023-019-1100-y
pmc: PMC6537225
doi:
Substances chimiques
Prealbumin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
116Subventions
Organisme : Grants from the Japan Society for the Promotion of Science KAKENHI
ID : 26860372
Pays : International
Organisme : Grants from the Japan Society for the Promotion of Science KAKENHI
ID : 25870541
Pays : International
Organisme : Grants from the Japan Society for the Promotion of Science KAKENHI
ID : 24249036
Pays : International
Références
Biochem Biophys Res Commun. 1999 Oct 22;264(2):365-70
pubmed: 10529370
Amyloid. 1999 Dec;6(4):282-8
pubmed: 10611950
Arch Neurol. 2002 Nov;59(11):1771-6
pubmed: 12433265
Cell. 2005 Apr 8;121(1):73-85
pubmed: 15820680
Muscle Nerve. 2007 Oct;36(4):411-23
pubmed: 17554795
Clin Chem. 2009 Jun;55(6):1223-7
pubmed: 19372189
Amyloid. 2011 Jun;18(2):53-62
pubmed: 21463231
Mod Pathol. 2011 Dec;24(12):1533-44
pubmed: 21822203
Neurology. 2012 Feb 28;78(9):637-43
pubmed: 22345221
Amyloid. 2012 Jun;19 Suppl 1:43-4
pubmed: 22494066
Neurology. 2012 Aug 21;79(8):785-92
pubmed: 22843282
Muscle Nerve. 2013 Feb;47(2):157-62
pubmed: 23169427
Orphanet J Rare Dis. 2013 Feb 20;8:31
pubmed: 23425518
N Engl J Med. 2013 Aug 29;369(9):819-29
pubmed: 23984729
JAMA. 2013 Dec 25;310(24):2658-67
pubmed: 24368466
Ann Clin Biochem. 2016 Jul;53(Pt 4):508-10
pubmed: 26342004
Amyloid. 2017 Mar;24(1):66-67
pubmed: 28393577
J Mass Spectrom. 1996 Jan;31(1):112-4
pubmed: 8799265
Biochem Biophys Res Commun. 1996 Nov 12;228(2):480-3
pubmed: 8920938
Eur J Clin Invest. 1997 Nov;27(11):956-9
pubmed: 9395793
Anal Chem. 1999 Jan 15;71(2):452-9
pubmed: 9949732